Trial Profile
A phase I/II study to investigate the efficacy and safety of durvalumab (MEDI4736) in combination with idelalisib in patients with haematological cancers or solid tumours
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 28 Apr 2015
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Idelalisib (Primary)
- Indications Breast cancer; Diffuse large B cell lymphoma; Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- 28 Apr 2015 New trial record